Bio-Quant and TEF Labs Sign Agreement to Jointly Develop Novel Fluorescent Dyes for Use in High Throughput Screening.Business Editors SAN DIEGO San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. & AUSTIN, Texas--(BUSINESS WIRE)--Oct. 2, 2001 Bio-Quant, Inc., a developer of advanced multiplex detection systems, and TEF TEF Tracheoesophageal fistula, see there Labs, a fluorescent probe company, announced today that they have entered into an agreement to jointly develop novel dyes for use in assays and tools for High Throughput Screening (HTS HTS Heights HTS Harmonized Tariff System HTS High Throughput Screening (biomolecular assay screening) HTS High-Throughput Screening (Pharmaceutical Industry) HTS Harmonized Tariff Schedule ). HTS is one of several tools pharmaceutical and biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. employ to find leads for drug candidates or to conduct basic biological research. Scientists screen biological samples, using HTS, to identify compounds worth pursuing as drug candidates. Under the agreement, Bio-Quant and TEF Labs will develop the dyes using TEF Labs' proprietary chemistry, which will be applied to Bio-Quant's proprietary Fluorescence Infrared Bioluminescence bioluminescence (bī'ōl  'mĭnĕs`əns), production of light by living organisms. Reader (FLIBR) and ChemoReader devices. FLIBR is a video image plate reader designed to read absorbance absorbance /ab·sor·bance/ (-sor´bans)1. in analytical chemistry, a measure of the light that a solution does not transmit compared to a pure solution. Symbol . 2. , luminescence luminescence, general term applied to all forms of cool light, i.e., light emitted by sources other than a hot, incandescent body, such as a black body radiator. , fluorescence and infrared, and is capable of detecting very low optical levels from virtually any fluorescent dye Noun 1. fluorescent dye - a yellow dye that is visible even when highly diluted; used as an absorption indicator when silver nitrate solution is added to sodium chloride in order to precipitate silver chloride (turns pink when no chloride ions are left in solution and available; ChemoReader is an imaging device designed to read our proprietary lateral 96 well HTS chemotaxis assay Chemotaxis assays are experimental tools for evaluation of chemotactic ability of prokaryotic or eukaryotic cells. A wide variety of techniques are known and applied for such reason. . TEF Labs' proprietary chemistry will allow the development of the first visible wavelength ratiometric calcium indicator for use in High Throughput Screening (HTS) cellular signaling assays. Leakage resistance and membrane versions of the new dyes will significantly enhance flexibility in High Throughput Screening assay design and eliminate the need to wash the cells after their loading with the dye. HTS enables scientists to rapidly assay thousands of compounds in search of biological activity for drug discovery. The drug discovery process begins with the identification of biological molecules that are involved in disease (disease targets) and the synthesis of chemical compounds (drug candidates), which may be able to act on these targets. Dr. Bassam Damaj, president and chief executive officer of Bio-Quant, said, "The FLIBR instrument is the ultimate machine for high throughput screening. Bio-Quant is committed to the field of High Throughput Screening and to adding value to its technology platform. This joint development effort with TEF Labs is an excellent example of this approach in an important drug discovery area with a large market potential. We are confident we can build on TEF Labs' innovation with our own imaging technology." The advanced multiplex technologies being developed by Bio-Quant are designed to facilitate simultaneous detection and quantification of several markers of a disease, allowing physicians to assess the presence and progression of the disease. About Bio-Quant, Inc. Bio-Quant, Inc. a leader in the multiplex detection systems and devices for High Throughput screening. Its proprietary cutting-edge Multiplex Detection Technology gives the ability to test both qualitatively and quantitatively more than one disease marker at the same time in either blood or tissue samples. Its new FLIBR imaging technology and molecular drug discovery tools provides the pharmaceutical and drug development industry with faster ways and less expensive tools to develop drugs. For more information, visit Bio-Quant's web site at http://www.bio-quant.com. About TEF Labs www.TEF Labs.com TEF Labs is a fluorescent probes developer with a specialty in ion indicators for cell signaling Cell signaling is part of a complex system of communication that governs basic cellular activities and coordinates cell actions. The ability of cells to perceive and correctly respond to their microenvironment is the basis of development, tissue repair, and immunity as well as . Products include probes for calcium, sodium, pH. The founder and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Dr. Akwazi Minta is a co-inventor with Dr. Roger Tsien of such probes as Fluo-3, Rhod-2, and SBFI and a pioneer in the filed of fluorescent probes chemistry -- TEF Labs is a leader in the market of fluorescent ion indicators. This press release may contain forward-looking statements regarding Bio-Quant Inc. Actual results may differ materially from those described in the press release as a result of a number of factors, including but not limited to the following: There can be no assurance that any product in the Bio-Quant product pipeline will be successfully developed or manufactured. The Company undertakes no obligation to revise or update any such forward-looking statement to reflect events or circumstances after the date of this release. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion